Anti-inflammatory agents

Liokareas' Rx High Polyphenol Extra Virgin Olive Oil Takes The Gold Medal At The World's Healthiest Olive Oil Competition Hosted in Spain

Retrieved on: 
Tuesday, June 1, 2021
World Geographical Scheme for Recording Plant Distributions, Plants, Phenols, Mediterranean cuisine, Phenylethanoids, Anti-inflammatory agents, Aldehydes, Oleocanthal, Phytochemicals, Olive oil, Polyphenol, Olive

PITTSBURGH, June 1, 2021 /PRNewswire/ --Liokareas Olive Oil Company received top honors as their Rx High Polyphenol Extra Virgin Olive Oil received the gold medal at the World's Best Healthy Extra Virgin Olive Oil Contest for its healthy composition in Fatty Acids Oleocanthal Bio Phenols.

Key Points: 
  • PITTSBURGH, June 1, 2021 /PRNewswire/ --Liokareas Olive Oil Company received top honors as their Rx High Polyphenol Extra Virgin Olive Oil received the gold medal at the World's Best Healthy Extra Virgin Olive Oil Contest for its healthy composition in Fatty Acids Oleocanthal Bio Phenols.
  • The Liokareas Rx High Polyphenol Extra Virgin Olive Oil (HPEVOO) is extrordinarily rich in Polyphenols, and specifically, Oleocanthal.
  • "As a fifth-generation olive oil producer, we are incredibly proud to be awarded #1 in world's healthiest olive oil competition.
  • At Liokareas Olive Oil, our vision has always been to produce the best olive oil that our consumers can get their hands on.

Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study

Retrieved on: 
Tuesday, April 20, 2021
Chemical compounds, Organic compounds, Heterocyclic compounds, Anti-inflammatory agents, Azetidines, Baricitinib, Breakthrough therapy, Pyrazoles, Sulfonamides

In both investigational trials, a statistically significant proportion of patients treated with baricitinib achieved the primary endpoint of hair regrowth across the two dosing regimens at Week 36 compared to patients treated with placebo.

Key Points: 
  • In both investigational trials, a statistically significant proportion of patients treated with baricitinib achieved the primary endpoint of hair regrowth across the two dosing regimens at Week 36 compared to patients treated with placebo.
  • "\nThe BRAVE-AA trial program was designed to evaluate the efficacy and safety of baricitinib in adult patients with severe AA.
  • Based on interim results of the Phase 2 portion of BRAVE-AA1 at Week 12, baricitinib 2-mg and 4-mg once-daily doses were selected for further evaluation in the Phase 3 portion of the study.
  • BRAVE-AA2 is a multicenter, randomized, double-blind, placebo-controlled study evaluating the baricitinib 2-mg and 4-mg dosing regimens versus placebo.

Endourage Begins Human Clinical Trial to Test If Proprietary Hemp-Flower Formulation Eases Symptoms of Post-Acute COVID-19 Syndrome

Retrieved on: 
Tuesday, April 13, 2021
Alternative medicine, Retail, Health, Infectious diseases, Tobacco, Clinical trials, Pharmaceutical, Clinical trials, Clinical research, Design of experiments, Drugs, Health, Medical research, Orphan drugs, Anti-inflammatory agents, Placebo-controlled study, Cannabidiol, Placebo, Open-label trial

It will measure the efficacy and safety of Formula C for people with (PACS).

Key Points: 
  • It will measure the efficacy and safety of Formula C for people with (PACS).
  • The study is a single blind, placebo-controlled trial with an open label arm.
  • Participants will not know if they are receiving the Formula C which includes terpenes and cannabidiol (CBD), or the placebo during the first 28-day arm.
  • Sterling\xe2\x80\x99s mandate is to ensure compliance with federal regulations to protect the rights and welfare of human participants in research studies.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210413005424/en/\n'

I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests Addition of Icatibant is Unlikely to Impact Critically Ill COVID-19 Patients

Retrieved on: 
Thursday, April 15, 2021
Medical specialties, Health, Occupational safety and health, Anti-inflammatory agents, Orphan drugs, Intensive care medicine, Respiratory therapy, COVID-19, Icatibant, Mechanical ventilation

Today QLHC announced that, in addition to the razuprotafib and apremilast arms, the icatibant portion of the trial has concluded.

Key Points: 
  • Today QLHC announced that, in addition to the razuprotafib and apremilast arms, the icatibant portion of the trial has concluded.
  • There were no safety concerns associated with icatibant in the trial.\nThe I-SPY COVID Trial is a phase II, open label, adaptive platform trial being conducted in critically ill COVID-19 patients who are receiving high flow oxygen or mechanical ventilation.
  • "Icatibant did not impactpatients critically ill with COVID-19 when compared to those receiving backbone therapy alone.
  • Under the terms of the collaboration agreement, Quantum Leap Healthcare Collaborative is the trial sponsor and manages all study operations.

Olatec Therapeutics’ Lead Compound, Dapansutrile, a Selective NLRP3 Inhibitor, Prevents the Inflammatory Response and Restores Cognitive and Behavioral Deficits in a Mouse Model of Alzheimer’s Disease

Retrieved on: 
Tuesday, December 29, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Anti-inflammatory agents, Neurology, NLRP3, Alzheimer's disease, Dapansutrile, Neuroinflammation, MTOR

Olatec Therapeutics LLC (Olatec) today announced the publication of data demonstrating the benefits of its selective NLRP3 inhibitor, dapansutrile, in a mouse model of Alzheimers Disease (AD).

Key Points: 
  • Olatec Therapeutics LLC (Olatec) today announced the publication of data demonstrating the benefits of its selective NLRP3 inhibitor, dapansutrile, in a mouse model of Alzheimers Disease (AD).
  • The study shows oral dosing with dapansutrile inhibits pathophysiological inflammatory processes, recovers significant cognitive losses and prevents neuroinflammation in the brains of transgenic mice induced with Alzheimers Disease (AD).
  • Prof. Dr. Korte said, "Our findings are another important piece of the puzzle in Alzheimer's disease research.
  • Alzheimers disease is a progressive neurological disorder resulting in memory loss, behavioral symptoms, and loss of ability to perform daily activities.

Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata

Retrieved on: 
Friday, October 30, 2020
Chemical compounds, Organic compounds, Heterocyclic compounds, Pyrazoles, Breakthrough therapy, Sulfonamides, Anti-inflammatory agents, Azetidines, Baricitinib, Incyte, Ruxolitinib

Data from the Phase 2 portion of BRAVE-AA1, an ongoing Phase 2/3 study evaluating the safety and efficacy of baricitinib in adult patients with AA will be shared.

Key Points: 
  • Data from the Phase 2 portion of BRAVE-AA1, an ongoing Phase 2/3 study evaluating the safety and efficacy of baricitinib in adult patients with AA will be shared.
  • In March, the FDA granted Breakthrough Therapy designation to baricitinib for the treatment of AA based on positive Phase 2 results from BRAVE-AA1.
  • For more information about the Lilly data being presented at this year's virtual Fall Clinical Dermatology meeting, please visit https://fallclinical.health/fall-clinical-20 .
  • Baricitinib, an oral JAK1/JAK2 inhibitor discovered by Incyte, is developed by Lilly under license from Incyte.

While Gilead/Galapagos' Filgotinib Will Have to Contend with the Early Success of AbbVie's Rinvoq in the US Rheumatoid Arthritis Market, Eli Lilly's Olumiant is Likely to be the More Formidable Foe in the EU

Retrieved on: 
Wednesday, July 1, 2020
Chemical compounds, Medical specialties, Organic compounds, Anti-inflammatory agents, RTT, Immunosuppressants, Baricitinib, Sulfonamides, Tofacitinib, Janus kinase inhibitor, Pfizer, Arthritis

In the US, swift adoption of AbbVie's Rinvoq is already eroding the leadership position of Pfizer's Xeljanz, the first-to-market and historically dominant JAK inhibitor in RA.

Key Points: 
  • In the US, swift adoption of AbbVie's Rinvoq is already eroding the leadership position of Pfizer's Xeljanz, the first-to-market and historically dominant JAK inhibitor in RA.
  • For example, Olumiant was FDA approved for the treatment of RA in 2018, giving Xeljanz a six-year head start in the US market.
  • Of note, nearly one-third of US rheumatologists indicated they would prescribe substantially more Olumiant if the 4mg dose was approved.
  • A parallel service, RealTime Dynamix: Rheumatoid Arthritis (US) , includes access to a quarterly report series tracking the US RA market.

EULAR 2020: Lilly Shares New Data for OLUMIANT® in Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE)

Retrieved on: 
Wednesday, June 10, 2020
Chemical compounds, Medical specialties, Organic compounds, RTT, Eli Lilly and Company, Rheumatology, Anti-inflammatory agents, Baricitinib, Sulfonamides, Arthritis, Rheumatoid arthritis

Lilly is pleased to present long-term safety and efficacy data in patients treated with OLUMIANT for rheumatoid arthritis," says Dr. Doron Sagman, Vice President, R&D and Medical Affairs, Eli Lilly Canada.

Key Points: 
  • Lilly is pleased to present long-term safety and efficacy data in patients treated with OLUMIANT for rheumatoid arthritis," says Dr. Doron Sagman, Vice President, R&D and Medical Affairs, Eli Lilly Canada.
  • Patients in this study were treated with OLUMIANT 4-mg once daily, an approved dose outside of North America.
  • The safety data from long-term extension of multiple baricitinib trials in rheumatoid arthritis, demonstrated ongoing safety of approximately 3,700 patients followed for up to 8.4 years.
  • For more information about the Lilly data presented at this years virtual EULAR congress, please visit https://www.congress.eular.org/scientific_programme.cfm .

Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology

Retrieved on: 
Wednesday, June 3, 2020
FDA, Health, Sports, Cricket, Pharmaceutical, Biotechnology, RTT, Dermatitis, Organ systems, Medicine, Clinical medicine, Monoclonal antibodies, Anti-inflammatory agents, Light therapy, Abrocitinib, Atopic Dermatitis, Pfizer’s Immunokinase Inhibitor Leadership

Eligible subjects completing the 12-week treatment period of the study had the option to enter a long-term extension (LTE) study, B7451015.

Key Points: 
  • Eligible subjects completing the 12-week treatment period of the study had the option to enter a long-term extension (LTE) study, B7451015.
  • Subjects discontinuing early from treatment, or who were otherwise ineligible for the LTE study, entered a 4-week follow up period in this study.
  • JADE MONO-2 is the second trial in the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program.
  • Abrocitinib received Breakthrough Therapy designation from the FDA for the treatment of patients with moderate to severe AD in February 2018.

Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata

Retrieved on: 
Monday, March 16, 2020
Chemical compounds, Medical specialties, Organic compounds, Anti-inflammatory agents, Rheumatology, Azetidines, Baricitinib, Pyrazoles, Sulfonamides

We look forward to working with the FDA to further explore baricitinib's potential to become the first approved treatment option for these individuals."

Key Points: 
  • We look forward to working with the FDA to further explore baricitinib's potential to become the first approved treatment option for these individuals."
  • The FDA Breakthrough Therapy designation is based on the positive Phase 2 results of Lilly's adaptive Phase 2/3 study BRAVE-AA1, which evaluated treatment with baricitinib versus placebo in adult patients with AA.
  • Baricitinib is currently approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).
  • SERIOUS INFECTIONS: Patients treated with Olumiant are at risk for developing serious infections that may lead to hospitalization or death.